Phase 3 N=18 Nasal Packing as a Drug Delivery System Postoperatively in Chronic Sinusitis With Polyposis
Chronic Sinusitis · Polyposis
Primary: Olfaction — 20.2; 19.8 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=288 Prednisone Timed-Release Tablet (TRT) Study: Modified-Release (MR) Formulation of Prednisone Compared to Standard Immediate-Release (IR) Prednisone in Participants With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Relative Change From Baseline in Duration of Morning Stiffness at Week 12 — -22.7; -0.4 percent change
Phase 3 N=1,522 VA Augmentation and Switching Treatments for Improving Depression Outcomes
Major Depressive Disorder
Primary: Rate of Protocol Remission of Symptoms of Major Depressive Disorder — 114; 136; 146 Participants — p=0.076
Phase 3 N=675 4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Moderate to Severe Chronic Plaque-Type Psoriasis
Primary: Long-term Safety and Tolerability of Secukinumab — 88.3; 92.0; 92.9; 78.2 Percentage of participants
Phase 3 N=511 IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose
Iron Deficiency Anaemia
Primary: Number of Subjects With an Haemoglobin (Hb) Increase of ≥ 2 g/dL From Baseline at Any Time From Week 1 to Week 5 — 226; 83 participants
Phase 3 N=347 MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects
Asthma
Primary: Number of Participants Who Experienced On-treatment Adverse Events (AE) and On-treatment Serious Adverse Events (SAE) — 326; 79 Participants
Phase 3 N=882 Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass
Coronary Artery Bypass Grafting · Mitral Valve Surgery · Low Cardiac Output Syndrome
Primary: Number of Dual Efficacy Endpoint Events — 56; 48 events
Phase 3 N=412 Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive Disorder
Major Depressive Disorder
Primary: The Mean Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score — -9.2; -7.2 units on a scale
Phase 3 N=242 Immediate-Release Oxycodone Capsules Study in Cancer Pain
Cancer
Primary: Numerical Rating Scale (NRS) — 3.91; 3.87 scores on a scale
Phase 3 N=350 Clinical Trial Comparing Two Protocols Using Intravenous (IV) Hydromorphone
Acute Pain
Primary: Number of Patients With Satisfactory Pain Management at 60 Minutes — 112; 113 Participants
Phase 3 N=28 Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis
Secondary Hyperparathyroidism, Chronic Kidney Disease
Primary: Number of Participants With Adverse Events — 9; 10; 1; 2 Participants
Phase 3 N=86 Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study
Friedreich's Ataxia
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs — 78; 61; 4; 0 participants
Phase 3 N=1,560 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Fallopian Tube Clear Cell Adenocarcinoma · Fallopian Tube Endometrioid Adenocarcinoma · Fallopian Tube Mucinous Adenocarcinoma
Primary: Median Progression-free Survival — 24.9; 27.3; 26.0 months — p=0.341
Phase 3 N=968 Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
Acne Vulgaris
Primary: Absolute Change in Facial Inflammatory Lesion Counts at Week 12 — -15.3; -10.1 lesion count — p=< 0.0001
Phase 3 N=517 Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
Hypercholesterolaemia
Primary: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis — -51.8; -3.9; -48.2; 0.8 percent change — p=<0.0001